Equip ISGlobal - Títol

Equip ISGlobal

Barbara Harding

Barbara Harding

Investigadora associada Malalties no transmissibles i medi ambient

Barbara Harding’s research focuses on cardiovascular health and circadian disruption. She currently works with data from multiple night shift studies, examining biomarkers and mechanisms related to cardiovascular health among night shift workers. She is a work package co-lead of the EPHOR project, a co-investigator in an ongoing microbiome project among night shift workers, and the PI of the CARDIO-SHIFTS study.

Barbara joined ISGlobal as a postdoctoral fellow in 2020. Her background is in Exercise Science (BS) and Epidemiology (PhD). She completed her doctoral studies in epidemiology at the University of Washington in Seattle, WA, where she studied commonly used medications and survival from ovarian cancer. Prior to coming to ISGlobal, she worked as a postdoctoral fellow at the Cardiovascular Health Research Institute in Seattle, WA, where she studied cardiovascular health and ageing.

Línies de recerca

  • Cardiovascular health
  • Circadian disruption
  • Ageing
  • Exposome
  • Pharmacoepidemiology

Publicacions principals

  • Harding BN, Skene DJ, Espinosa A, et. al. Metabolic profiling of night shift work –The HORMONIT study. Chronobiol Int. 2022,39(11):1508-1516.
  • Harding BN, Austin TR, Floyd DS, et al. Self-reported marijuana use and cardiac arrhythmias. The Multi-Ethnic Study of Atherosclerosis. Am J Cardiol 2022, 177:48-52
  • Harding BN, Castano-Vinyals G, Palomar-Cros A, et al. Changes in Melatonin and Sex Steroid Hormone Production in Men as a Result of Rotating Night Shift Work –the HORMONIT Study. Scand J Work Environ Health. 2022 Jan 1;48(1):41-51.
  • Harding BN, Hawley CN, Kalinowski J, et al. Relationship between social support and incident hypertension in the Jackson Heart Study: a cohort study. BMJ Open 2022;12:e054812.
  • Harding BN, Avoundjian T, Heckbert SR, et al. HIV viremia and risk of stroke among people living with HIV who are using antiretroviral therapy. Epidemiology. 2021;32(3):457-464.
Publicador de continguts